Company intelligence / Profile preview
Revelation Biosciences
San Diego, CA, USrevbiosciences.com ↗
- Ownership
- Public · REVB
- Development stage
- Other
01
Overview
Clinical-stage biopharma developing Gemini (PHAD® formulation) to rebalance inflammation through trained immunity. Recent milestones include Phase1b initiation in CKD patients and GMP manufacturing completion[3][9]. Pipeline spans therapeutic and diagnostic programs targeting organ diseases and infections.
- Therapeutic areas
- Infectious DiseasesNephrology
- Modalities
- Immunologic-based therapiesIntravenous formulationsIntranasal immunomodulators
- Industry
- Biotech
02
Drug pipeline
5 assets4 more assets in the full pipeline.
03
Partnerships
LifeSci Capital LLC(mentioned in financial context)[3]Petra Acquisition Inc.(merger partner)[8]
04
Financials
- Market cap
- $2M
- Total revenue
- $0
- Enterprise value
- $-6.3M
Beyond the preview
Go deeper on Revelation Biosciences.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Revelation Biosciences.